Advertisement
Screener

Coya Therapeutics, Inc. (COYA) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.0 / 5 stars · 13/32 Roast Me

Coya Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Coya Therapeutics, Inc. (COYA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-11

  • Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
  • Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
  • Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
  • Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
  • Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2026-06-300.00%
10-Q · filed 2026-08-11
2026-03-310.00%
10-Q · filed 2026-05-12
2025-12-310.00%
10-K · filed 2026-03-16
2025-09-300.00%
10-Q · filed 2025-11-12
2025-06-300.00%
10-Q · filed 2026-08-11
2025-03-310.00%
10-Q · filed 2026-05-12
2024-12-310.00%
10-K · filed 2026-03-16
2024-09-300.00%
10-Q · filed 2025-11-12
2024-06-300.00%
10-Q · filed 2025-08-12
2024-03-310.00%
10-Q · filed 2025-05-13
2023-12-310.00%
10-K · filed 2024-03-19
2023-09-300.00%
10-Q · filed 2023-11-08
2023-06-300.00%
10-Q · filed 2023-08-08
2023-03-310.00%
10-Q · filed 2023-05-10
2022-12-310.00%
10-K · filed 2023-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Immuneering Corp (IMRX)United States$0.113B-12.51
Quantum Cyber N.V. (QUCY)$0.113B
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
MEDICINOVA INC (MNOV)United States$0.130B-6.04
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31